(Q38126418)

29 August 2017

New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? (English)

1 reference

29 August 2017

1 reference

1

Amirhossein Sahebkar

1 reference

29 August 2017

2

Gerald F Watts

1 reference

29 August 2017

1 December 2013

1 reference

Cardiovascular Drugs and Therapy

29 August 2017

1 reference

29 August 2017

27

1 reference

29 August 2017

559-567

1 reference

29 August 2017

6

1 reference

Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver

29 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Familial hypobetalipoproteinemia: genetics and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Mechanisms of disease: genetic causes of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Familial hypercholesterolemia: the lipids or the genes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Role of insulin resistance in familial combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Metabolic origins and clinical significance of LDL heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The clinical relevance of low-density-lipoproteins size modulation by statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Small dense LDL: An emerging risk factor for cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a): an emerging cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Elevated lipoprotein(a)--a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a): intrigues and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Familial lipoprotein disorders in patients with premature coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a) and ischemic heart disease--a causal association? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Reducing residual risk for patients on statin therapy: the potential role of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Proprotein convertases in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

New approaches to target microsomal triglyceride transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Abetalipoproteinemia: two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein apheresis: state of the art and novelties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Lipoprotein(a) metabolism: potential sites for therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6479-4

10.1007/S10557-013-6479-4

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23913122